ZYXI logo

Zynex Stock Price

Symbol: NasdaqGS:ZYXIMarket Cap: US$44.5mCategory: Healthcare

ZYXI Share Price Performance

US$1.45
-6.14 (-80.90%)
60.8% undervalued intrinsic discount
US$3.70
Fair Value
US$1.45
-6.14 (-80.90%)
60.8% undervalued intrinsic discount
US$3.70
Fair Value
Price US$1.45
AnalystHighTarget US$3.70
AnalystLowTarget US$3.00
AnalystConsensusTarget US$2.85

ZYXI Community Narratives

AN
AnalystHighTarget
AnalystHighTarget·Updated
Fair Value US$3.70 60.8% undervalued intrinsic discount

Telehealth And Home Healthcare Will Redefine Pain Management

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget·Updated
Fair Value US$3.00 51.7% undervalued intrinsic discount

TRICARE Suspension Will Exacerbate Revenue Challenges While Prospects Improve

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget·Updated
Fair Value US$2.85 49.1% undervalued intrinsic discount

Aging Populations And FDA Moves Will Unlock New Markets

0users have liked this narrative
0users have commented on this narrative
17users have followed this narrative

Recent ZYXI News & Updates

No updates

Zynex, Inc. Key Details

US$144.8m

Revenue

US$35.2m

Cost of Revenue

US$109.6m

Gross Profit

US$138.3m

Other Expenses

-US$28.7m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-0.95
Gross Margin
75.70%
Net Profit Margin
-19.79%
Debt/Equity Ratio
4,684.7%

Zynex, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About ZYXI

Founded
1996
Employees
1000
CEO
Thomas Sandgaard
WebsiteView website
www.zynex.com

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

U.S. Market Performance

  • 7 Days: 2.3%
  • 3 Months: 12.9%
  • 1 Year: 20.2%
  • Year to Date: 8.3%
The Consumer Staples sector gained 3.2% while the market remained flat over the last week. As for the longer term, the market has risen 20% in the past 12 months. Earnings are forecast to grow by 15% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading